Literature DB >> 30922877

Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations.

Jose M Pacheco1, D Ross Camidge2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30922877     DOI： 10.1016/S2213-2600(19)30112-2

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  2 in total

1.  Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.

Authors:  Athanasios R Paliouras; Marta Buzzetti; Lei Shi; Ian J Donaldson; Peter Magee; Sudhakar Sahoo; Hui-Sun Leong; Matteo Fassan; Matthew Carter; Gianpiero Di Leva; Matthew G Krebs; Fiona Blackhall; Christine M Lovly; Michela Garofalo
Journal:  EMBO Mol Med       Date:  2020-06-17       Impact factor: 12.137

2.  Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study.

Authors:  Sara Elena Rebuzzi; Francesco Facchinetti; Marcello Tiseo
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.